Natera (NASDAQ:NTRA) Insider John Fesko Sells 1,688 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 1,688 shares of Natera stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $204.10, for a total value of $344,520.80. Following the completion of the sale, the insider directly owned 187,511 shares in the company, valued at $38,270,995.10. This represents a 0.89% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $144,319.91.
• On Tuesday, February 3rd, John Fesko sold 3,594 shares of Natera stock. The shares were sold at an average price of $231.02, for a total value of $830,285.88.

Natera Trading Down 2.7%

Shares of NTRA opened at $194.75 on Thursday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The stock’s 50 day moving average is $202.22 and its two-hundred day moving average is $213.80. The firm has a market capitalization of $27.71 billion, a PE ratio of -127.29 and a beta of 1.68.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The company had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the previous year, the company earned ($0.41) EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.71 EPS for the current year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Recent operating results and analyst interest provide a bullish backdrop: Natera reported an upside quarter (Feb. 26) with revenue and EPS above consensus, and multiple firms maintain buy/overweight views and price targets above the current price — a structural tailwind if execution continues.
• Positive Sentiment: Large institutional buying in recent quarters (e.g., Coatue, Wellington added sizable positions) indicates continued conviction from some allocators, which can limit downside and support recovery after volatility. Quiver Quant: Natera shares slide
• Neutral Sentiment: Multiple insider sales have been announced (CEO, CFO and other executives) but were executed under pre‑arranged Rule 10b5‑1 plans and primarily to cover tax withholdings on vested awards — routine from a governance perspective but can be interpreted differently by the market. See one SEC disclosure for the CFO sale on Apr. 29. CFO Form 4 (Apr 29)
• Negative Sentiment: Near-term de‑risking ahead of the May 7 earnings print has pressured the stock — several market summaries point to position‑sizing into the report, which increases short‑term volatility and drove selling momentum. Quiver Quant: Natera shares slide
• Negative Sentiment: Analyst caution and supply/overhang concerns: a recent downgrade to hold (circulated in April) and a string of Form 144/insider sale disclosures have kept investors focused on potential selling pressure; investors may also be scrutinizing management’s 2026 revenue/gross‑margin guidance as a tougher setup after strong prior growth. Yahoo Finance: Should You Be Bullish on Natera?

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Horizon Investments LLC lifted its position in shares of Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC lifted its position in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 45 shares during the period. Savvy Advisors Inc. lifted its position in shares of Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 46 shares during the period. Siemens Fonds Invest GmbH lifted its position in shares of Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH raised its position in shares of Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after purchasing an additional 62 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on NTRA. Morgan Stanley lowered their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. TD Cowen reiterated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Citigroup assumed coverage on shares of Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target for the company. Finally, Robert W. Baird lifted their price target on shares of Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.